Roswell Park Cancer Institute
Research Interests: Phase I and Phase II clinical trial designs in oncology; application of exact testing methods to binary and categorical data
William E. Brady, PhD, earned his MS in statistics from the University of Wisconsin (UW) in 1993 and his PhD in biostatistics from the University at Buffalo (UB) in 2012. He joined the Roswell Park Cancer Institute (RPCI) faculty and was appointed director of the Biostatistics Core Resource in 2012. Prior to joining the RPCI Biostatistics Department as a biostatistical consultant in 2005, he spent nine years in the pharmaceutical industry-most recently at Merck & Co., Inc. Dr. Brady has collaborated on studies ranging from translational research and preclinical work at RPCI to phase I and phase II clinical trials at the NRG (formerly Gynecologic Oncology Group [GOG]) to phase III and IV industry trials, including contributions to three successful New Dug Applications (NDAs) to epidemiologic studies at RPCI, GOG and UW.
Brady currently serves on NCI's Ovarian Task Force, RPCI's Phase I Committee, Scientific Review Committee (SRC), Cancer Center Support Grant (CCSG) Steering Committee, and previously served on its Institutional Review Board (IRB). He has served or does serve on the NRG/GOG's Developmental Therapeutics, Phase I, Rare Tumor, Comparative Effectiveness, and Health Outcomes Research Committees.